Clinical trial NCT02400320: Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
Official title: Cumulative Skin Irritation Study Evaluating the Skin Irritancy Potential of Topical Analgesic Vovilup Spray Containing a Combination of Diclofenac, Menthol, Methyl Salicylate and Linseed Oil and Comparing it With a Marketed Formulation - Iodex Ultragel
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Skin Irritation
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2015-03-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to determine local skin safety of a topical analgesic spray containing a combination of diclofenac, methyl salicylate, menthol and compare it with a topical analgesic gel containing a combination of diclofenac, methyl salicylate, and menthol.


Eligibility criteria: Inclusion Criteria

1. Healthy male or female volunteers aged at least 18 years.
2. Good general, physical and mental health in the opinion of the investigator or medically qualified designee:

   * No clinically significant and relevant abnormalities in medical history or upon physical examination.
   * Absence of any condition that could affect the volunteer's safety or well being or their ability to understand and follow study procedures and requirements.
3. Healthy volunteers who do not have excessive hair on the volar aspect of the forearm(s).
4. Healthy volunteers should understand and be willing to fully comply with all study procedures and restrictions.
5. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
6. Females of childbearing potential, using an effective contraceptive method for at least one month before the beginning of the study, and willing to use throughout the study

Exclusion Criteria

1. Volunteers having recent history (within one year) of alcohol or other substance abuse as determined by medical history.
2. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
3. Previous participation in similar study with similar products.
4. Volunteer has any visible skin disease at the site of application that, in the opinion of the investigator, will interfere with the skin assessments.
5. Volunteer has current or relevant previous history of serious, severe or unstable physical or psychiatric illness, or medical disorders, such as current or previous history of hepatic or renal diseases (impairment) or peptic ulcer as determined by medical history.
6. Volunteer has a history of hypersensitivity (e.g. asthma, bronchospasm, rhinitis, urticaria, nasal polyps) to aspirin, diclofenac, other non steroidal anti-inflammatory drugs (NSAIDs), menthol or any of the excipients in the test product(s).
7. Volunteer is receiving systemic or topical NSAIDs, other oral or topical analgesics or antihistamine within 3 days of visit 1, or other medication (such as corticosteroids within 3 weeks of visit 1) which, in the opinion of the investigative personnel, will interfere with the study results.
8. Female volunteers who are pregnant, planning to become pregnant during the study, or are breast-feeding.
9. Female volunteers who have positive pregnancy test.
10. Volunteers who are employees of the sponsor or study site or an immediate family member (e.g. partner, offspring, parents, siblings or sibling's offspring) of such employees.
11. Any skin disorder at the test site that in the investigator's judgement can affect the readings of the test result
12. Any concomitant medications that in the investigator's judgement can confound or alter test results or evaluation of adverse events.

Primary outcomes:
measure: Mean cumulative irritation score
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: